MX2021001870A - Metodo para tratar cancer pancreatico. - Google Patents
Metodo para tratar cancer pancreatico.Info
- Publication number
- MX2021001870A MX2021001870A MX2021001870A MX2021001870A MX2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A MX 2021001870 A MX2021001870 A MX 2021001870A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- treating pancreatic
- pancreatic cancer
- administering
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente solicitud se describe un método para tratar cáncer pancreático en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto inhibidor de la polimerización de tubulina. De manera más particular, en la presente solicitud se describe un método para tratar adenocarcinoma ductal pancreático en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto inhibidor de la polimerización de tubulina de tipo pirimidina inversa sustituida solo o en combinación con otros agentes quimioterapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862719526P | 2018-08-17 | 2018-08-17 | |
PCT/US2019/046972 WO2020055544A2 (en) | 2018-08-17 | 2019-08-17 | Method for treating pancreatic cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001870A true MX2021001870A (es) | 2021-07-15 |
Family
ID=69778374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001870A MX2021001870A (es) | 2018-08-17 | 2019-08-17 | Metodo para tratar cancer pancreatico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210236492A1 (es) |
EP (1) | EP3836932A2 (es) |
JP (1) | JP2021535198A (es) |
CN (1) | CN113164479A (es) |
AU (1) | AU2019340402A1 (es) |
BR (1) | BR112021002630A2 (es) |
CA (1) | CA3109386A1 (es) |
IL (1) | IL280800A (es) |
MX (1) | MX2021001870A (es) |
TW (1) | TW202021961A (es) |
WO (1) | WO2020055544A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113710670A (zh) * | 2019-02-28 | 2021-11-26 | Ptc医疗公司 | 治疗多发性骨髓瘤的方法 |
EP3947379A4 (en) * | 2019-03-27 | 2022-12-21 | PTC Therapeutics, Inc. | COMBINATIONS FOR USE IN A METHOD OF TREATMENT OF SARCOMA |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6412503B2 (ja) | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス, インコーポレイテッド | 置換逆ピリミジンBmi−1阻害剤 |
EP3071553A4 (en) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
-
2019
- 2019-08-17 AU AU2019340402A patent/AU2019340402A1/en active Pending
- 2019-08-17 MX MX2021001870A patent/MX2021001870A/es unknown
- 2019-08-17 BR BR112021002630-4A patent/BR112021002630A2/pt unknown
- 2019-08-17 JP JP2021532285A patent/JP2021535198A/ja active Pending
- 2019-08-17 CA CA3109386A patent/CA3109386A1/en active Pending
- 2019-08-17 US US17/267,988 patent/US20210236492A1/en active Pending
- 2019-08-17 WO PCT/US2019/046972 patent/WO2020055544A2/en active Application Filing
- 2019-08-17 CN CN201980068196.9A patent/CN113164479A/zh active Pending
- 2019-08-17 EP EP19859682.7A patent/EP3836932A2/en active Pending
- 2019-08-19 TW TW108129532A patent/TW202021961A/zh unknown
-
2021
- 2021-02-10 IL IL280800A patent/IL280800A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113164479A (zh) | 2021-07-23 |
JP2021535198A (ja) | 2021-12-16 |
AU2019340402A2 (en) | 2021-04-01 |
AU2019340402A1 (en) | 2021-03-25 |
BR112021002630A2 (pt) | 2021-05-11 |
WO2020055544A2 (en) | 2020-03-19 |
US20210236492A1 (en) | 2021-08-05 |
CA3109386A1 (en) | 2020-03-19 |
TW202021961A (zh) | 2020-06-16 |
EP3836932A2 (en) | 2021-06-23 |
IL280800A (en) | 2021-04-29 |
WO2020055544A3 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201906001B (en) | Combination therapy for the treatment or prevention of tumours | |
EP4302835A3 (en) | Methods of treating ovarian cancer | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
EA201890768A2 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
PH12014502048A1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
IL280158A (en) | Methods of treating cancer with the PI3K inhibitor, GDC-0077 | |
AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
EA202192575A1 (ru) | Соединения dbait в сочетании с ингибиторами киназ для лечения рака | |
EA201792346A1 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) | |
MX2022001004A (es) | Inhibidores de enzimas. | |
EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
WO2020115491A3 (en) | Immune checkpoint inhibitor in combination with sonodynamic therapy | |
EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
MX2021001870A (es) | Metodo para tratar cancer pancreatico. | |
MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
MX2019006694A (es) | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. | |
MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
MX2020007342A (es) | Compuestos de sililetinilo hetarilo como inhibidores de la nitrificacion. | |
MX2022003686A (es) | Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial. |